tadalafil has been researched along with nitrendipine in 2 studies
| Studies (tadalafil) | Trials (tadalafil) | Recent Studies (post-2010) (tadalafil) | Studies (nitrendipine) | Trials (nitrendipine) | Recent Studies (post-2010) (nitrendipine) |
|---|---|---|---|---|---|
| 1,742 | 392 | 1,089 | 2,170 | 378 | 83 |
| Protein | Taxonomy | tadalafil (IC50) | nitrendipine (IC50) |
|---|---|---|---|
| G-protein coupled receptor 55 | Homo sapiens (human) | 1.4652 | |
| Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | 0.0152 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 0.3 | |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Rattus norvegicus (Norway rat) | 0.0013 | |
| Voltage-dependent L-type calcium channel subunit alpha-1D | Rattus norvegicus (Norway rat) | 0.0013 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 3 | |
| Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | 0.0152 | |
| Voltage-dependent L-type calcium channel subunit alpha-1S | Rattus norvegicus (Norway rat) | 0.0013 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 10 | |
| Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | 0.0152 | |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | 0.0152 | |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C | Homo sapiens (human) | 1.85 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Jung, F; Leithäuser, B; Park, JW | 1 |
1 trial(s) available for tadalafil and nitrendipine
| Article | Year |
|---|---|
Sublingual application of liquid nitrendipine does not result in critical hypotension in healthy volunteers under phosphodiesterase-5 inhibition.
Topics: Administration, Sublingual; Adult; Angina Pectoris; Blood Pressure; Carbolines; Cardiovascular Diseases; Dosage Forms; Drug Interactions; Erectile Dysfunction; Humans; Hypotension; Male; Nitrendipine; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Tadalafil | 2008 |
1 other study(ies) available for tadalafil and nitrendipine
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |